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Abstract.  Vascular  endothelial cells (ECs) seeded 
sparsely on extracellular matrix (ECM) will proliferate 
in the absence of exogenous basic fibroblast growth 
factor (bFGF). This ECM will also stimulate neurite 
outgrowth in PC12 cells in the absence of exogenous 
growth factors.  We have previously shown that bFGF 
is found in subendothelial ECM (Vlodavsky,  I., J. 
Folkman, R.  Sullivan, R. Fridman, R.  Ishai-Michaeli, 
J.  Sasse, and M. Klagsbrun.  1987. Proc.  Natl.  Acad. 
Sci.  USA.  84:2292-2296)  and in basement membranes 
(Folkman, J., M. Klagsbrun, J.  Sasse, M. Wadzinski, 
D.  Ingber, and I. Vlodavsky.  1988. Am.  J.  Pathoi. 
130:393-400).  The actual requirement of ECM- 
associated bFGF for the growth of ECs and differenti- 
ation of PC12  cells was shown in two ways. First, 
polyclonal anti-bFGF antibodies added to subendothe- 
lial  ECM inhibited both EC proliferation and PC12 
neurite outgrowth. Secondly, PF-HR-9 cells, which do 
not synthesize bFGF and which produce an ECM not 
permissive for EC proliferation and PC12  neurite out- 
growth, were transfected with bFGF cDNA.  PF-HR-9 
cells transfected with bFGF, but not with the dominant 
selectable marker SV2-neomycin, were found to ex- 
press bFGF and to produce an ECM which did sup- 
port both EC proliferation and PC12  differentiation. 
The ECM-mediated stimulatory effects were inhibited 
by anti-bFGF antibodies but not by anti-nerve growth 
factor antibodies or nonimmune rabbit IgG. These 
results indicate that bFGF associated with ECM is a 
required ECM component for ECM-mediated cell 
proliferation and differentiation. 
ROLE for cell-matrix interactions in the control of cell 
proliferation  and  differentiation  has  been  demon- 
strated both in vivo and in vitro (6,  19, 21, 23, 44). 
The extracellular  matrix (ECM) ~  deposited by cultured bo- 
vine corneal endothelial cells (ECs) stimulates proliferation 
of  vascular ECs (17) and neurite extension in the sympathetic 
cell line PC12 (10, 42). Both these activities are also induced 
by basic fibroblast growth factor (bFGF) when added to the 
tissue culture medium (36, 41). Recently, we have extracted 
bFGF-like growth factors from the subendothelial ECM pro- 
duced by cultured  corneal  ECs  (39) and from Descemet's 
membranes of  bovine cornea (8). We have also demonstrated 
that the ECM-associated bFGF is bound to heparan sulfate 
proteoglycans (HSPGs) (2), suggesting that HSPGs provide 
a natural storage depot for bFGF and possibly other heparin- 
binding growth factors (32). However, in view of  the molecu- 
lar complexity of ECM and basement membranes, we could 
1. Abbreviations  used in this paper:  bFGF, basic fibroblast growth factor; 
CE-ECM, corneal endothelial cell extracellular matrix; ECs, endothelial 
cells;  ECM,  extracellular  matrix;  HSPG,  heparan  sulfate proteoglycan; 
NGE  nerve growth factor. 
not ascribe a specific biological activity to the ECM-bound 
bFGE 
The present  study was undertaken  to investigate the in- 
volvement of the ECM-associated bFGF in its induction of 
EC proliferation and PC12 differentiation. For this purpose 
we applied two approaches: (a) use of anti-bFGF antibodies 
which inhibit the activity of soluble bFGF (26); and (b) com- 
parison of the ECM produced by PF-HR-9 mouse endoder- 
mal carcinoma cells (3, 25), which do not synthesize bFGE 
and by PF-HR-9 cells transfected with the gene for bFGE 
Our results indicate that ECM induction of EC proliferation 
and  PCI2  neuronal  differentiation  is  mediated  by  ECM- 
bound bFGE 
Materials and Methods 
Cells 
Cultures of bovine corneal ECs were established from steer eyes as previ- 
ously described (16).  Stock cultures were maintained in DME (1  g  glu- 
cose/liter) supplemented with 10%  bovine calf serum, 5 % FCS, penicillin 
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NY) at 37°C in 10% C(h-humidified incubators. Partially purified, brain- 
derived bFGF (100 ng/ml) was added every other day during the phase of 
active cell growth. Cloned populations of adult bovine aortic ECs were iso- 
lated and cultured in DME containing 10% bovine calf serum, as described 
(41). Neomycin-resistant  PCI2 cells (clone PCI2 NI), originally established 
from a transplantable rat pheochromocytoma (18),  were cultured in DME 
(4.5  g  glucose/liter) supplemented with  10%  calf serum,  penicillin (50 
U/ml), and streptomycin (50/zg/ml). PF-HR-9 cells derived from a differen- 
tiated  mouse endodermal carcinoma (3)  (kindly provided by Dr.  R. H. 
Kramer, University of California, San Francisco, CA), were maintained in 
DME  (4.5  g  glucose/liter) containing  10%  FCS and antibiotics, as de- 
scribed (25). Cells were maintained at 37°C in 10% CO2-humidified incu- 
bators and subcultured weekly at a  1:10 split ratio after dissociation with 
saline containing 0.05%  trypsin, 0.01 M  sodium phosphate, pH 7.2, and 
0.02%  EDTA (Gibco Laboratories). 
Preparation of Dishes Coated with ECM 
Cultures of bovine corneal ECs were dissociated from stock cultures (pas- 
sage 2-5) with saline containing 0.05%  trypsin, 0.01 M sodium phosphate, 
pH 7.2, and 0.02%  EDTA, and plated into 35-mm tissue culture dishes (Fal- 
con Labware Division, Becton, Dickinson and Co., Oxnard, CA) at an ini- 
tial  density of 5  x  104  cells/dish. Cells  were maintained as described 
above, except that bFGF was not added, and 5% dextran T-40 was included 
in the growth medium. 6-8 d after the cells reached confluency, the suben- 
dothelial ECM was exposed by dissolving (3 min at 22"C) the cell layer with 
a solution containing 0.5% Triton X-100 and 20 mM NI-I4OH in PBS, fol- 
lowed by four washes in PBS (43).  The ECM remained intact and firmly 
attached to the entire area of the tissue culture dish. Alternatively, the ECs 
were removed intact by exposure (10-20 min) to 2 M urea in DME, a proce- 
dure that exposes the subendothelial ECM without lysing the cells (13). 
Similar results were obtained with both methods. 1 cm  2 of ECM has been 
shown to contain a total of ,x,l.8 U ('x,0.36 ng) of endogenous bFGF activity 
(39). We have previously demonstrated that the polar secretion of ECM by 
corneal ECs and the firm interaction of this ECM with the tissue culture 
plastic, provide an appropriate system to obtain a basement membrane-like 
substrate,  free of cellular elements (17, 43).  The presence of nuclei or 
cytoskeletal elements could not be detected on the denuded ECM when 
plates were examined by phase-contrast microscopy, scanning electron mi- 
croscopy, or indirect immunofluorescence, using antiactin and antivimentin 
antibodies, or the benzimidole derivative, Hoechst 33258,  for nuclear stain- 
ing (13).  Moreover, ECM prepared after a 24-h exposure of subconfluent 
corneal EC cultures to [3H]thymidine was devoid of labeled material. Like- 
wise, no labeled cell surface components remained associated with the ECM 
after solubilization (Triton/Nl-b, OH) of lactoperoxidase-iodinated corneal 
ECs that were plated on ECM for 24 h. No serum proteins could be iden- 
tiffed in the ECM (12). 
For preparation of PF-HR-9 ECM, cells (105/35-mm  dish) were seeded 
into tissue culture dishes precoated with fibronectin (50 #g/dish) to enforce 
a firm adhesion of the ECM to the plastic substratum. Ascorbic acid (50 
#g/ml) was added on days 2 and 4 and the ECM denuded 6-7 d after seeding 
the cells, as described above for corneal ECs (25). In contrast with the ECM 
produced by corneal ECs (CE-ECM), some cellular debris was always left 
adhering to the PF-HR-9 ECM. The CE-ECM contained mainly fibronec- 
tin, laminin, collagen types I, III, and IV, elastin, and sulfated proteogly- 
cans (i.e., HSPGs, dermatan sulfate proteoglycans, and chrondroitin sulfate 
proteoglycans) (15, 43). Major constituents of the HR-9-ECM were lami- 
nin, entactin, collagen type IV, and HSPGs (15, 25). 
Transfection of  PF-HR-9 Cells with bFGF 
Expression Piasmid 
bFGF expression plasmid (pbFGF) was constructed by inserting the Eco 
RI-flanked bFGF eDNA sequence from pJJll-1  plasmid (1) in the 5' to 3' 
orientation behind the SV-40 early promoter sequences into the Eco RI site 
of the p Jay3 mammalian expression vector (33). The plasmid (pbFGF) was 
transfected into PF-HR-9 cells, as described (37).  Briefly,  calcium phos- 
phate precipitate of DNA (0.1 #g pSV2-neo plus 40 #g of either NIH 3T3 
DNA or pbFGF DNA) was added to 2  ×  10-cm dishes of subconfluent PF- 
HR-9 cells in DME containing 5 % calf serum. After 8 h of incubation with 
these DNA mixtures, the medium was aspirated and cells shocked with 15 % 
glycerol in PBS for 3 rain. Cultures were refed with DME containing 10% 
calf serum, 50 U/ml penicillin, and 50 #g/ml streptomycin, incubated for 
24 h, and subcultured (1:8)  in the same medium supplemented with 0.5 
mg/ml G418 (Gibeo Laboratories). The selection medium was replaced ev- 
ery 3 d for 2 wk. About 20 colonies of  PF-HR-9 cells transfect~ with pSV2- 
neo (38), with or without pbFGF, were cloned and expanded into cell lines. 
Lysates of these cell lines were screened for bFGF activity using (a) Balb/c 
3T3 cell [3H]thymidine incorporation assay (8,  39); and (b) immunoblot 
and immunoprecipitation analysis with anti-bFGF antibodies (7, 33,  39). 
PF-HR-9 clone HR9/neo transfected with pSV2-neo alone and clone HR9/ 
bFGF transfected with pSV2-neo plus pbFGF were used in the present study. 
Growth Factor  Activity 
Assay for DNA synthesis in 3T3 cells was performed as described (8, 39). 
Briefly, Balb/c 3T3 cells were plated at half confluence on 0.3-cm  2 microti- 
ter  wells in  DME  supplemented with  10%  calf serum.  After reaching 
confluence (2-3 d), the cells were further incubated for a minimum of 5 d. 
Samples and [3H]thymidine (1 p,  Ci/well) were then added to the quiescent 
cells and, after an incubation period of 32-40 h, DNA synthesis was assayed 
by measuring the radioactivity incorporated into TCA-insoluble material. A 
unit of 3T3 cell growth factor activity (•70,000  cpm) was defined as the 
amount of growth factor in 0.25 ml required to stimulate half-maximal DNA 
synthesis in 3T3 cells. Lysates of 106 bFGF-transfected HR9 cells (clone 
HR9/bFGF) contained 80-100 U of growth factor activity.  On the basis of 
previous studies, it is estimated that pure bFGF has a specific activity of 
",'5 U/ng. Two methods were used to measure proliferation of bovine aortic 
ECs (9).  (a) For measurements of DNA synthesis, ECs were seeded at a 
low density (1  x  103 cells per 2-cm  2 well of a 24-weU plate) in 1 ml DME 
containing 10% calf serum, bFGF was added on days 2 and 4 and [3H]thy- 
midine (2.5 #Ci/well) added on day 5 after seeding. 2 h later, the cultures 
were washed and assayed for [3H]thymidine incorporation into DNA (9). 
(b) ECs were seeded at a clonal density (400 cells per 35-ram dish). On 
day 9 after seeding, the cultures were fixed with 3.7 % formaldehyde and cell 
colonies were stained with 0.1% crystal violet (9, 39). 
Column Chromatography 
Heparin-Sepharose affinity chromatography was carried out as described 
(8, 22, 39). Cells were grown for 5-6 d until they reached confluence. The 
medium  was removed and  cells (6-8  ×  107) were resuspended at  107 
cells/ml in 10 mM Tris-HCl, pH 7, 1 M NaCI, and lysed by sonication. Cell 
lysates diluted to 0.1 M NaCI were applied to heparin-Sepharose columns 
(3 ml) and bFGF was eluted with an 80-ml gradient of 0.2-3.0 M  NaCI, 
at a flow rate of 30-40 ml/h at 4°C. Fractions (4 ml) were collected and 
tested for stimulation of DNA synthesis in 3T3 cells (22). 
Neutralizing Anti-b  FG  F Antibodies 
Anti-bFGF polyclonal antibodies that block the mitogenic effect of bFGF 
on ECs and the ability of bFGF to stimulate neurite outgrowth in PC12 cells 
were prepared as described previously (26).  Briefly,  New Zealand white 
rabbits were injected twice with human recombinant bFGF (Takeda,  Chem- 
ical Industries, Osaka, Japan;  140 #g/rabbit per injection) and serum was 
collected from the ear 7 d after the second injection. The titer of the serum 
was determined using an enzyme-linked immunoabsorbent assay in which 
a 96-well plate was coated with 50 ng of bFGF. An anti-bFGF IgG fraction 
(final concentration of  4 mg/ml) was prepared by protein A-Sepharose  column 
chromatography. The anti-bFGF IgG fraction at a concentration of 200 #g/ 
ml completely inhibited the mitogenic activity of bFGF for 3T3 cells (26). 
Immunoblotting 
Electrophoretic transfer blots were carded out as previously described (8, 
22, 39). Proteins within active fractions isolated by heparin-affinity  chroma- 
tography were dialyzed, lyophilized, and electrophoresed on  15%  SDS- 
polyacrylamide gels. The gel was equilibrated for 30 rain in transfer buffer 
containing 1% SDS, rinsed briefly in transfer buffer without SDS, and over- 
laid  with 0.1-#m-pore nitrocellulose paper (Schleicher &  Schuell,  Inc., 
Keene, NH). The electrophoretic transfer was performed at 40 V (Transblot 
cell; Bio-Rad Laboratories, Richmond, CA) overnight at 4°C. The nitrocel- 
lulose paper was either stained for protein with Aurodye-colloidal gold re- 
agent (Janssen Life Sciences Products, Beerse, Belgium) or incubated with 
anti-bFGF antisera raised against synthetic peptide representing an internal 
region (positions 33-43) ofbFGE as previously described (8, 22). Immuno- 
reactivity was visualized by successive incubations with biotinyla~d goat 
anti-rabbit antibodies, peroxidase-conjugated strepavidin, and 4-chloro- 
naphthol substrate (22, 39). 
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and ECM-induced Stimulation of  EC Proliferation 
EC [3H]thymidine  incorporation 
Plastic  Plastic  +  FGF  ECM 
cpm  x  10  -~  cpra  x  10  -3  cpm  X  10  -3 
Control  8.3  56.5  84.0 
+  Anti-bFGF  6.8  9.7  20.5 
+  Nonimmune IgG  8.1  55.3  82.5 
Bovine aortic ECs were seeded (5  ×  102 cells/cm  2) in DME plus 10% calf sc- 
ram into regular and CE-ECM--coated wells of 24-weU tissue culture plates. 
Recombinant bFGF (2 ng/ml), rabbit  anti-bFGF IgG (40 #g/ml), or nonim- 
mune rabbit IgG were added to some of the ECM-coated wells on days ! and 
3 after seeding. I~H]Thymidine  (2.5 #Ci/well) was added on day 5  for 2  h 
and the amount of thymidine incorporation into TCA-insoluble material was 
determined. Each data point represents the mean of six determinations and the 
variation between different determinations did not exceed 15% of the mean. 
Immunoprecipitation 
Ceils cultured in  lO-cm dishes were radiolabeled for  16 h using 5  ml of 
cysteine-free DME  supplemented with  5%  calf serum and  50  #Ci  of 
[35S]cysteine  (sp  act  >1,000  Ci/mmol;  New  England  Nuclear,  Boston, 
MA). The ceils were washed twice with PBS and scraped into I ml cell iysis 
buffer (50 mM Tris-HCl, pH 8.0,  100 mM NaCI, 5 mM MgCI2, and 0.5% 
NP-40 detergent). After a 5-min incubation on ice, the nuclei were pelleted 
by a  5-min centrifugation in an Eppendorf centrifuge (Brinkman Instru- 
ments Co., Westbury, NY). The supernatant was preadsorbed with 5 #l nor- 
mal rabbit serum and 40 #1 protein A-Sepharose for 4 h at 4°C. The protein 
A-Sepharose was centrifuged and the supernatant incubated for 16 h at 4"C 
with 5 #1 of anti-amino terminus peptide rabbit antibody (22). 20 #i protein 
A-Sepharose was added for I h of further incubation. The pellet was washed 
four times with cell lysis buffer containing 1% Triton X-100,  1% sodium 
deoxycholate, and 1% aprotinin solution. 20 ~1 SDS-PAGE sample buffer 
was added to the washed pellet and the sample electrophoresed on SDS- 
PAGE. 
Results 
Effect of  Anti-bFGF Antibodies on ECM Stimulation 
of EC Proliferation  and PC12 Differentiation 
We have previously demonstrated that the ECM produced by 
cultured corneal ECs replaces the requirement that vascular 
ECs have for bFGF in order to proliferate and to express 
their normal phenotype (9, 17). Incubation of this ECM with 
polyclonal anti-bFGF antibodies inhibited by 70-80%  the 
ECM-stimulated incorporation of [3H]thymidine into sparse- 
ly seeded vascular ECs (Table I). These antibodies also in- 
hibited the mitogenic activity of soluble bFGF (Table I) (26). 
Nonimmune rabbit IgG had no inhibitory effect.  The basal 
incorporation of [3H]thymidine into ECs maintained on reg- 
ular tissue culture plastic in the absence of bFGF did not ex- 
ceed 10% of that obtained on ECM and was either little or 
not affected by the anti-bFGF antibodies (Table I). Inhibition 
(65-80%  in different experiments) of EC proliferation was 
also obtained when the cells were seeded at a clonal cell den- 
sity on ECM that was pretreated (30 min) with the anti- 
bFGF antiserum. Antibodies (40 #g/ml) were added on days 
2 and 4 and formation of cell colonies was evaluated 8 d after 
seeding. 
Soluble bFGF  induces  neurite extension  in  PC12  cells 
(36). This neuronal differentiation was inhibited by the poly- 
clonal anti-bFGF antibodies (Fig.  1). PC12 cells plated on 
ECM in the absence of added bFGF or nerve growth factor 
(NGF) responded by extension of neuronal processes 24- 
48 h after seeding.  At 3-4 d after seeding, these neurites 
were at least tenfold longer than the cell diameter (Fig. 2 A). 
Neurite outgrowth ceased after 5-7 d in culture when some 
cell rounding and detachment was observed.  Addition of 
anti-bFGF antibodies, 12 and 36 h after seeding, resulted in 
a complete inhibition of neurite outgrowth (Fig. 2 B). The 
cells remained flattened and firmly bound to the ECM, fol- 
lowed by 20-30%  cell detachment 6-8 days after seeding. 
There was no effect to anti-NGF antibodies (Fig. 2 D) and 
to nonimmune rabbit IgG (Fig. 2 C). Addition of anti-bFGF 
antibodies 48-72 h after seeding the PC12  ceils on ECM, 
resulted in retraction of preextended neurites. These results 
suggest that stimulation of both EC proliferation and PC12 
morphological differentiation by ECM are mediated by the 
ECM-associated bFGF-like molecules. 
Expression of bFGF by PF-HR-9 Cells Transfected 
with bFGF cDNA 
PF-HR-9 Cells secrete an underlying basement membrane- 
like ECM (15, 25) which is not mitogenic for vascular ECs. 
This ECM also failed to induce extension of neuronal pro- 
cesses  in  PC12  cells.  Similar results  were obtained with 
the ECM produced by a neomycin-resistant  clone (HR9/neo) 
of PF-HR-9 cells transfected with the dominant selectable 
marker pSV2-neo (38) (Figs. 4 B and 5 D; see next section). 
When lysates of HRg/neo cells were subjected to heparin- 
Sepharose chromatography, no growth factor activity for 3T3 
fibroblasts and vascular ECs was eluted with a salt gradient 
ranging from 0.2 to 3.0 M NaCI (Fig. 3 A). Metabolic label- 
ing of HR9/neo cells with [35S]cysteine followed by immu- 
noprecipitation of cell lysates with anti-bFGF antibodies 
failed to reveal any bFGF synthesized by these cells (Fig. 3 
C). In contrast, a  clonal cell population (HR9/bFGF) de- 
rived by cotransfecting the expression vector pbFGF with 
pSV2-neo (33) expressed bFGF, as determined by (a) elution 
of growth-promoting activity from heparin-Sepharose  at 
1.6 M NaCI (Fig. 3 A); (b) Western blot analysis of the peak 
fractions  with  anti-bFGF  antibodies  directed  against  an 
internal region of bFGF (Fig. 3 B); and (c) immunoprecipi- 
tation of [35S]cysteine-labeled cells (Fig. 3 C). The immu- 
no-detected bFGF could be displaced by an excess of the 
immunizing peptide (corresponding to positions  1-12 and 
33-43 of bFGF) (Fig. 3, B and C). 
Growth- and Differentiation-promoting  Activities of 
ECM Produced by bFGF-expressing PF-HR-9 Cells 
ECM produced by control PF-HR-9 cells (clone HR9/neo) 
transfected with pSV2-neo alone and by PF-HR-9 cells (clone 
HR9/bFGF)  transfected with both pSV2-neo  and pbFGF 
were compared for their ability to support proliferation of 
vascular ECs and neurite extension in PC12 cells. As demon- 
strated in Fig. 4 B, the ECM produced by HR9/neo cells had 
little or no effect on clonal growth of vascular ECs. Both the 
number and size of EC colonies were similar or at most 
slightly higher than those obtained on regular plastic tissue 
culture dishes (Fig. 4 A). In contrast, the ECM produced by 
PF-HR-9 cells which expressed bFGF induced an extensive 
clonal growth of vascular ECs (Fig. 4 C), similar to that ob- 
served with the ECM produced by corneal ECs (Fig. 4 D). 
Stimulation of both clonal growth and DNA synthesis in vas- 
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bodies  on  bFGF-induced  neurite 
outgrowth  in  PC12 cells.  PC12 
cells  were  seeded  (105 cells/dish) 
in DME plus 10% calf serum into 
35-mm  culture  dishes.  Cultures 
were  incubated  with  recombinant 
bFGF (15 ng/ml) in the absence (A) 
or presence (B) of polyclonal anti- 
bFGF antibodies (40/zg IgG/ml). 
Phase-contrast  micrographs  were 
taken 5 d after seeding. Bar, 50 ttm. 
cular ECs plated on the ECM produced by HR9/bFGF cells 
was inhibited  by anti-bFGF antibodies to an extent which 
was similar to that observed with cells seeded on the ECM 
produced by corneal ECs. 
Seeding of PC12 cells on ECM produced by transfected 
clones of PF-HR-9 cells resulted in neurite outgrowth on the 
ECM produced by cells (clone HR9/bFGF) which expressed 
bFGF (Fig. 5 A), but not by control cells (clone HR9/neo) 
which showed no detectable synthesis of bFGF (Fig. 5 D). 
Induction of neuronal differentiation was inhibited by anti- 
bFGF antibodies (Fig. 5 B), but not by anti-NGF antibodies 
(Fig.  5  C). 
Sequestration of bFGF by heparan sulfate in the ECM may 
take place when the cell layer is solubilized and the ECM ex- 
posed. The following results suggest that this is not the case 
and that bFGF is deposited into the ECM by intact cells be- 
fore the actual removal of the cell layer. First, clonal growth 
of vascular ECs was stimulated to a similar extent regardless 
The Journal of Cell Biology, Volume 109, 1989  826 Figure 2.  Effect of anti-bFGF antibodies on CE-ECM-induced extension of neuronal processes  in PC12 cells.  PC12 cells were seeded 
(10  s cells per dish) in DME plus  10% calf serum into 35-mm culture dishes coated with CE-ECM. Rabbit anti-bFGF antibodies (B), 
nonimmune rabbit IgG (C), or anti-NGF antibodies (D) were added (40 #g/ml) to some of the dishes  12 and 36 h after seeding. Control 
PC12 cells were maintained on ECM alone (A). Phase-contrast  micrographs  were taken on day 4.  Bar, 20/~m. 
of whether the ECM was exposed by lysing the cells in the 
absence or presence of heparin. Heparin (50 #g/ml) was in- 
cluded in the lysis solution to inhibit binding of bFGF to the 
ECM's heparan sulfate when the corneal ECs are lysed (2). 
In a second experiment corneal ECs were seeded at a conflu- 
ent density  (106 cells per 35-mm dish) on top of PF-HR-9 
ECM.  A  short time (10-20 min) after cell attachment and 
flattening, the cells were lysed with Triton and NH4OH and 
the underlying  ECM tested for mitogenic activity. The ex- 
posed ECM failed to promote clonal growth of vascular ECs. 
In contrast, ECM exposed 7 d after seeding the same corneal 
ECs on top of the  nonpermissive HR-9 ECM,  was highly 
mitogenic for vascular ECs. Similar amounts of bFGF were 
determined  in lysates of confluent corneal  ECs prepared a 
short time and 7 d after seeding the cells (data not shown). 
Discussion 
It has now been widely accepted that ECMs play a  critical 
role in the control of cell growth, migration, and differentia- 
tion (6,  19, 21, 33, 44). Apparently, the substratum to which 
a cell is attached can determine the final shape that a cell will 
adopt and this shape can play a role in the response of cells 
to serum and plasma factors (7,  14).  Whereas some of these 
responses  are  mediated  by  various  macromolecular  con- 
stituents of the  ECM  (i.e.,  collagen,  laminin,  fibronectin, 
HSPGs) (4, 23), active molecules such as growth factors and 
enzymes that are firmly associated with the ECM may be in- 
volved as well. In previous studies we have reported on the 
identification and localization of bFGF in basement mem- 
branes of the cornea in  vivo (8) and  in the subendothelial 
ECM produced by cultured corneal ECs (39).  bFGF binds 
to heparan sulfate in the ECM (2), as was also reported for 
both granulocyte/macrophage colony-stimulating factor and 
Interleukin-3 (32). Heparin-binding growth factors have also 
been identified  in bone particles (20,  35). 
In  the  present  study  we  have applied  two  different  ap- 
proaches to investigate the involvement of the ECM-associ- 
ated bFGF in its induction of EC proliferation and PC12 neu- 
ronal differentiation.  Using the ECM produced by cultured 
Rogelj et al. Function  of bFGF in Extracellular  Matrix  827 Figure 3.  Analysis of bFGF expression in PF-HR-9 cells transfected with bFGF expression plasmid. Clonal cell lines of PF-HR-9 cells 
transfected with pSV2-neo alone (clone HR9/neo) or pSV2-neo plus pbFGF (clone HR9/bFGF) were obtained as described in Materials 
and Methods. (A) Heparin-Sepharose chromatography. Lysates of control PF-HR-9 cells (clone HR9/neo) transfected with pSV2-neo alone 
(o) and cells transfeeted with pSV2-neo plus pbFGF (clone HR9/bFGF) (o) were subjected to heparin-Sepharose affinity chromatography, 
as described in Materials and Methods. Fractions (4 ml) eluted with a salt gradient (0.2-3.0 M NaCI) were collected and aliquots (10--40 
t~l) tested for ability to stimulate DNA synthesis ([3H]thymidine incorporation) in 3"1"3  cells. (B) Western immunoblot analysis. Lanes 1 
and 3, recombinant bFGF; lanes 2 and 4, active fractions (pooled, dialyzed, and lyophilized) eluted from heparin-Sepharose and derived 
from lysates of clone HR9/bFGF; lane 5, molecular weight markers. Recombinant bFGF is the truncated 146 amino acid form of bFGF 
and therefore has a lower molecular weight than native bFGF (154 amino acids). Incubation of the nitrocellulose paper with anti-bFGF 
antibodies directed against a synthetic peptide representing an internal region (position 33-43) of bFGF (22), was performed in the absence 
(lanes I and 2) and presence (lanes 3 and 4) of excess peptide representing amino acids 33-43 of bFGE (C) Immunoprecipitation. Cells 
were subjected to metabolic labeling with [35S]eysteine  and immunoprecipitation with anti-bFGF amino-terminal peptide rabbit antibody 
(22), as described in Materials and Methods. As a control, 5/zg of the immunizing peptide (representing amino acids 1-12 of bFGF) were 
added to an identical sample. Lane 1, parental PF-HR-9 cells; lane 2, peptide control (PF-HR-9 cells immunoprecipitated in presence of 
5/~g peptide 1-12); lane 3, HR9/bFGF cells (pSV2-neo plus pbFGF); lane 4, peptide control of lane 3. 
ECs  we have demonstrated the ability of polyclonal anti- 
bFGF antibodies to inhibit the ECM-mediated stimulation of 
both EC proliferation and neurite outgrowth in PCI2 cells. 
Experiments performed with the PF-HR-9 mouse endoder- 
mal carcinoma cell line demonstrated that PF-HR-9 cells that 
do not synthesize bFGF deposit ECM which do not promote 
EC proliferation and PC12 differentiation. In contrast, PF- 
HRo9 cells that synthesize bFGF after transfection with the 
bFGF cDNA deposit ECM which induces both clonal growth 
of vascular ECs and extension of neuronal processes in PC12 
cells. These results clearly indicate that ECM-bound bFGF 
is playing a major role in stimulation of EC proliferation and 
PCI2 differentiation by ECM. 
Macromolecular constituents of the ECM and in particu- 
lar laminin and HSPGs have been reported to promote neu- 
rite outgrowth and to have profound effects within the de- 
veloping nervous system (27). The heparin-binding fragment 
of laminin  promotes  nerve cell  survival  and  neurite  out- 
growth (5). It may, therefore, well be that the interaction of 
macromolecules (i.e., laminin) and lower molecular weight 
constituents (i.e., bFGF) of the ECM with cell surface HSPG 
is playing a role in the initiation and maintenance of morpho- 
logical differentiation in  nerve cells.  Since the polyclonal 
anti-bFGF antibodies inhibit binding of bFGF to high affin- 
ity cell surface receptors (30) but not to heparin (26), interac- 
tion with specific cell surface sites is likely to be involved in 
the observed effects of ECM-bound bFGE 
ECM-associated bFGF  supports growth and differentia- 
tion, but it is not known whether ECM-bFGF must be bound 
or released to be biologically active, bFGF in ECM is bound 
to HSPGs with a low affinity (Kd =  6.1  X  10  -7 M) (2). The 
heparan sulfate might act to stabilize bFGF (11, 34). Release 
of bFGF from ECM can be brought about by heparan sul- 
fate-degrading enzymes, by heparin and heparan sulfate, and 
by  proteases  that  degrade  ECM  such  as  collagenase and 
tryspin (2).  ECs synthesize HSPGs and a small proportion 
of these molecules have the disaccharide structure of heparin 
(29).  These cells also produce plasminogen activator and 
collagenase whose  synthesis  is  stimulated  by bFGF  (28). 
Thus, ECs are capable of solubilizing bFGF from ECM. Al- 
ternatively, bFGF might act while still bound to the ECM. 
Of interest is our finding that PC12 neurites retract when 
anti-bFGF antibodies are added to ECM.  The continuous 
availability  of ECM-bound  bFGF  might  be  important  in 
maintaining differentiation of PC12 cells and maybe ECs as 
well. 
We propose that storage of bFGF in ECM provides a novel 
mechanism for regulation of capillary and connective tissue 
growth. For example, under normal conditions, ECs form a 
confluent, contact-inhibited monolayer in blood vessels and 
may not be responsive to ECM-bFGF. bFGF might also be 
mostly sequestered so as not to have access to ECs.  In re- 
sponse to alterations in basement membrane structure and 
turnover associated with normal (morphogenesis) and patho- 
logical  (wounding,  tumor  progression)  processes,  bFGF 
might be released from ECM,  possibly by proteases  and 
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HR9-ECM  on clonal  growth of 
vascular ECs. Bovine aortic ECs 
were  seeded  (300  cells/35-mm 
dish) on (A) regular tissue culture 
plastic;  (B)  ECM  produced  by 
HR9/neo  cells  (PF-HR-9  cells 
transfected with pSV2-neo alone); 
(C) ECM produced  by HR9/bFGF 
cells (transfection with pSV2-neo 
plus pbFGF); and (D) ECM pro- 
duced by corneal ECs. Cell colo- 
nies were stained with 0.1% crys- 
tal violet 9 d after seeding. 
heparan sulfate-degrading enzymes. Thus,  it is not neces- 
sary to argue that exogenous growth factors acting in a hor- 
monal manner are necessary for proliferative and differen- 
tiating events. On the contrary, tissues such as the cornea (8) 
or blood vessels might be capable of mobilizing their own 
bound growth factors for repairing damage. 
A striking feature of  bFGF is that it is mostly an intracellu- 
lar protein (39,  40) consistent with the lack of a consensus 
signal peptide in its gene (1). The identification of bFGF in 
basement membranes of the cornea (8) and of blood vessels 
(our unpublished observations) in vivo, and in the ECM pro- 
duced by cultured corneal ECs (39), suggest that bFGF is de- 
posited into ECM in a polar fashion, perhaps by forming an 
intracellular complex with HSPG. Although no demonstra- 
tion of such complex formation and bFGF deposition into 
ECM is presented, our preliminary results on the growth- 
promoting activity of ECM denuded in the absence and pres- 
ence of  heparin, and as a function of time in culture, strongly 
suggest that bFGF is in fact being secreted by intact ECs 
rather than sequestered by the ECM's heparan sulfate when 
the cell layer is removed and the ECM exposed. Such deposi- 
tion of bFGF during cell maintenance in culture may occur 
by means of a nontraditional secretory pathway that does not 
involve the consensus signal peptide. It is hoped that studies 
with PF-HR-9 cells transfected with the bFGF cDNA, with 
or without fusion with a  signal sequence (33), will further 
clarify the mode of bFGF deposition. 
Our studies with the ECM produced by corneal ECs and 
by HR9/bFGF cells demonstrated that the ECM was more 
effective than soluble bFGF in stimulating the proliferation 
of vascular ECs. It was also noted that the mitogenic effect 
of the ECM was not reduced to control levels by antibodies 
against bFGE In previous studies, we were unable to detect 
in ECM extracts any growth-promoting activity which does 
not bind to heparin-Sepharose or which elutes at a salt con- 
centration <1.5 M  NaCl (8,  39).  Although this result does 
not exclude the existence in ECM of growth factors and mito- 
genic matrix constitutents other than bFGF, it may well be 
that the matrix is more effective than soluble bFGF due to 
stabilization and protection of the ECM-bound bFGF (11). 
It is also conceivable that the anti-bFGF antibodies did not 
reduce the mitogenic effect of the ECM to control levels be- 
cause they failed to interact (steric hindrance) with all the 
ECM-associated bFGF molecules. 
Apart from bFGF, the ECM has been shown to contain 
plasminogen activator (both tissue type and urokinase type) 
and plasminogen activator inhibitor (reference  31 and our un- 
published results). It has also been reported that both plas- 
minogen (24)  and thrombin (la) bind firmly to ECM  and 
are protected from interaction with their natural inhibitors, 
~2-plasmin  inhibitor and antithrombin Ill, respectively.  These 
results further emphasize the significance of the ECM as a 
storage depot for biologically active molecules which bind 
to ECM and express functional properties that differ from 
those expressed by the same molecules in a fluid phase. The 
ECM may thus function as a solid-phase domain for anchor- 
Rogelj et al. Function of bFGF in Extracellular Matrix  829 Figure 5. Induction of neurite outgrowth in PC12 cells seeded on ECM produced by PF-HR-9 cells. PC12 cells were seeded on ECM depos- 
ited by HR9/bFGF cells (PF-HR-9 cells transfected with pSV2-neo plus pbFGF). Cultures were either untreated (A), or incubated with 
polyclonal anti-bFGF antibodies (B), or anti-NGF antibodies (C). Antibodies were added (40 #g/ml) 12 and 36 h after seeding and phase- 
contrast micrographs taken 3 d afterwards. PC12 cells were also seeded on the ECM produced by control PF-HR-9 cells transfected with 
pSV2-neo alone (clone HR9/neo) (D).  Bar,  20 #m. 
age of active molecules and cellular modulators, resulting in 
their localization,  stabilization,  and protection. 
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